The use of Cannabis-based Medications (CBMs) to manage psychological and behavioral issues in patients with dementia

The majority of patients with dementia will develop psychological and behavioral issues such as agitation, delusion, and hallucination during the course of their disease. These symptoms are very important because they will impact the communication between patients and caregivers, interfere in providing optimum care to patients and impact the quality of life of patients and their caregivers.Continue reading

Finnish Food Authority has pulled CBD products from the market

European Union has designated Cannabidiol(CBD) as Novel Food. Novel Foods are not allowed to be placed on the market without authorization. In 2019 a German court’s ruling classified CBD as either a prescription medicine or Novel Food and most recently the Finnish Food Authority has issued a recall of extracts containing cannabinoids, such as CBD-A. Availability of products containing CBD in the EU market is changing.